Nindanix is the first global generic of Nintedanib which is indicated in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first-line chemotherapy/immunotherapy and when no driver mutation is found to target.
The recommended dose of Nintedanib is 200 mg twice daily administered approximately 12 hours apart, on days 2 to 21 of a standard 21-day docetaxel treatment cycle.
If a dose is missed, administration should resume at the next scheduled time at the recommended dose.
The individual dose should not be increased beyond the recommended dose to make up for missed doses.
The recommended maximum daily dose of 400 mg should not be exceeded.
Patients should continue Nintedanib until disease progression or patients develop any intolerable toxicity after discontinuing docetaxel
It must not be taken on the same day as docetaxel
Nindanix should be taken approximately in every 12 hours (2 capsules in the morning & 2 capsules in the evening).
Nindanix should be taken with food/immediately after taking food.
Nindanix should be swallowed whole with water.
Quality of life of the patients is improved substantially in terms relieving cough, soothing pain and reducing shortness of breath after the treatment with Nintedanib + Docetaxel.